Advancing Harvard Medical School research, Dyno Therapeutics has raised $100m to advance its gene therapies based on AAV.

Dyno Therapeutics, a US-based gene therapy spinout of Harvard University, completed a $100m series A round yesterday that included GV, a corporate venturing subsidiary of internet and technology group Alphabet. Venture capital firm Andreessen Horowitz led the round, which also featured life sciences investment firm Casdin Capital and VC firms Obvious Ventures, Lux Capital, CRV…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.